<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03828058</url>
  </required_header>
  <id_info>
    <org_study_id>18-05876-FB</org_study_id>
    <nct_id>NCT03828058</nct_id>
  </id_info>
  <brief_title>Envarsus XL Immunosuppression Following Liver Transplantation</brief_title>
  <official_title>A 12 Month Single-center, Open Label, Randomized, Comparative Study to Evaluate Envarsus XL Steroid-free Rabbit Anti-thymocyte Globulin Induction on Renal Function and Health-related Quality of Life Following Liver Transplantation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Methodist Healthcare</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Methodist Healthcare</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The standard immunosuppressive regimen for liver transplantation includes twice daily
      tacrolimus (Prograf). In other transplantation models, there are potential benefits to
      extended release formulations as lower peak concentrations are thought to have lower rates of
      nephrotoxicity. Additionally, compliance with once daily medications is felt to be easier
      than twice daily medications. Our aim is to look at our prospective liver transplant group
      and see if once daily tacrolimus (Envarsus XR) results in improved renal function as well as
      improved health care quality of life.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">February 1, 2019</start_date>
  <completion_date type="Anticipated">December 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>The study will be a prospective, randomized, open label study comparing Envarsus XR with twice daily prograf.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in estimated glomerular filtration rate (eGFR) over the first year after liver transplant</measure>
    <time_frame>3, 6, and 12 months post-transplant</time_frame>
    <description>We will be assessing differences in renal function based on calculated eGFR by MDRD6 equation.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Quality of Life Assessment</measure>
    <time_frame>3, 6, and 12 months post-transplant</time_frame>
    <description>We will be using the RAND Short Form 36 (SF36) healthcare survey to assess patient reported quality of life across a broad spectrum ranging from physical health and function to emotional well being. Each sub scale score ranges from 0 (worse) to 100 (best).</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Recipients of Liver Transplant</condition>
  <arm_group>
    <arm_group_label>Envarsus XR</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Envarsus XR orally administered Daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Prograf</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Prograf PO administered twice daily Generic Name: tacrolimus
Dosage of prograf will be determined by trough levels and adjusted accordingly</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Envarsus XR</intervention_name>
    <description>Envarsus XR to be administered orally, once a day. Dosage will be adjusted as determined by trough blood levels.</description>
    <arm_group_label>Envarsus XR</arm_group_label>
    <other_name>ENVARSUS XR 0.75Mg Extended-Release Tablet</other_name>
    <other_name>ENVARSUS XR 1Mg Extended-Release Tablet</other_name>
    <other_name>ENVARSUS XR 4Mg Extended-Release Tablet</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Prograf</intervention_name>
    <description>Prograf 2 mg BID to be administered orally, twice a day. Dosage will be adjusted as determined by trough blood levels.</description>
    <arm_group_label>Prograf</arm_group_label>
    <other_name>Tacrolimus</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Provision of signed and dated informed consent form

          2. Stated willingness to comply with all study procedures and availability for the
             duration of the study

          3. Male or female, aged 18 years or older

          4. Recipients of a first-time liver transplant

          5. Serum Creatinine level less than 2.0 on Post-Operative Day 3-7

          6. Ability to take oral medication and be willing to adhere to the assigned
             immunosuppression regimen

          7. Agreement to adhere to Lifestyle Considerations (see section 5.3) throughout study
             duration

        Exclusion Criteria:

          1. Any prior use of tacrolimus or cyclosporine

          2. Recipients of prior organ transplant

          3. Need for hemodialysis in the week preceding or following liver transplantation

          4. Recipients of living donor liver or split deceased donor liver allografts

          5. Recipients of combined liver/kidney transplants

          6. Pregnancy or lactation

          7. Recipients of ABO incompatible liver allografts
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>James Eason, MD</last_name>
    <role>Study Director</role>
    <affiliation>The University of Tennessee Health Science Center, Department of Transplant</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ryan Helmick, MD</last_name>
    <phone>9015168954</phone>
    <email>rhelmick@uthsc.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Talana Vogel, EdD</last_name>
    <email>tvogel@uthsc.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Methodist Healthcare, University Hospital</name>
      <address>
        <city>Memphis</city>
        <state>Tennessee</state>
        <zip>38104</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Lori Kessler, PharmD</last_name>
      <phone>901-516-8633</phone>
      <email>lori.kessler@mlh.org</email>
    </contact>
    <investigator>
      <last_name>Luis Campos De La Borbolla, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Uchenna Agbim, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>James Eason, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Corey Eymard, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Peter Horton, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Daniel Maluf, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Valerie Mas, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Nosratollah Nezakatgoo, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Kadam P, Bhalerao S. Sample size calculation. Int J Ayurveda Res. 2010 Jan;1(1):55-7. doi: 10.4103/0974-7788.59946.</citation>
    <PMID>20532100</PMID>
  </reference>
  <results_reference>
    <citation>Abdelmalek MF, Humar A, Stickel F, Andreone P, Pascher A, Barroso E, Neff GW, Ranjan D, Toselli LT, Gane EJ, Scarola J, Alberts RG, Maller ES, Lo CM; Sirolimus Liver Conversion Trial Study Group. Sirolimus conversion regimen versus continued calcineurin inhibitors in liver allograft recipients: a randomized trial. Am J Transplant. 2012 Mar;12(3):694-705. doi: 10.1111/j.1600-6143.2011.03919.x. Epub 2012 Jan 10.</citation>
    <PMID>22233522</PMID>
  </results_reference>
  <results_reference>
    <citation>BÃ¤ckman L, Nicar M, Levy M, Distant D, Eisenstein C, Renard T, Goldstein R, Husberg B, Gonwa TA, Klintmalm G. FK506 trough levels in whole blood and plasma in liver transplant recipients. Correlation with clinical events and side effects. Transplantation. 1994 Feb 27;57(4):519-25.</citation>
    <PMID>7509516</PMID>
  </results_reference>
  <results_reference>
    <citation>Kong Y, Wang D, Shang Y, Liang W, Ling X, Guo Z, He X. Calcineurin-inhibitor minimization in liver transplant patients with calcineurin-inhibitor-related renal dysfunction: a meta-analysis. PLoS One. 2011;6(9):e24387. doi: 10.1371/journal.pone.0024387. Epub 2011 Sep 9.</citation>
    <PMID>21931704</PMID>
  </results_reference>
  <results_reference>
    <citation>Langone A, Steinberg SM, Gedaly R, Chan LK, Shah T, Sethi KD, Nigro V, Morgan JC; STRATO Investigators. Switching STudy of Kidney TRansplant PAtients with Tremor to LCP-TacrO (STRATO): an open-label, multicenter, prospective phase 3b study. Clin Transplant. 2015 Sep;29(9):796-805. doi: 10.1111/ctr.12581. Epub 2015 Aug 6.</citation>
    <PMID>26113208</PMID>
  </results_reference>
  <results_reference>
    <citation>Yoo MC, Vanatta JM, Modanlou KA, Campos L, Nezakatgoo N, Nair S, Eason JD. Steroid-free Liver Transplantation Using Rabbit Antithymocyte Globulin Induction in 500 Consecutive Patients. Transplantation. 2015 Jun;99(6):1231-5. doi: 10.1097/TP.0000000000000477.</citation>
    <PMID>25539464</PMID>
  </results_reference>
  <results_reference>
    <citation>Garnock-Jones KP. Tacrolimus prolonged release (EnvarsusÂ®): a review of its use in kidney and liver transplant recipients. Drugs. 2015 Feb;75(3):309-20. doi: 10.1007/s40265-015-0349-2. Review.</citation>
    <PMID>25613762</PMID>
  </results_reference>
  <results_reference>
    <citation>Niel OR, Berthoux F, Albano L, Dahan P, Aoudia R, Gugenheim J, Cassuto E. Long-term glomerular filtration rate in liver allograft recipients according to the type of calcineurin inhibitors. Transplant Proc. 2009 Oct;41(8):3329-32. doi: 10.1016/j.transproceed.2009.09.034.</citation>
    <PMID>19857743</PMID>
  </results_reference>
  <verification_date>January 2019</verification_date>
  <study_first_submitted>December 11, 2018</study_first_submitted>
  <study_first_submitted_qc>January 31, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">February 4, 2019</study_first_posted>
  <last_update_submitted>January 31, 2019</last_update_submitted>
  <last_update_submitted_qc>January 31, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">February 4, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tacrolimus</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

